PPIDT00241
Drug Information
| Name | Brentuximab vedotin |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB08870 |
| Type | biotech |
| Indication | Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with [doxorubicin], [vinblastine], and [dacarbazine]. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or progression. Finally, it may be used in the treatment of adult patients with cHL who have previously failed either auto-HSCT or at least two prior multi-agent chemotherapy regimens if they are not candidates for auto-HSCT.[L39789] Brentuximab vedotin is additionally indicated in the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL), or other CD30-expressing peripheral T-cell lymphomas (PTCL), in combination with [cyclophosphamide], doxorubicin, and [prednisone]. It may also be used as monotherapy in sALCL after therapeutic failure of a least one prior multi-agent chemotherapy regimen.[L39789] Brentuximab vedotin is also indicated in the treatment of primary cutaneous large anaplastic large cell lymphoma, or CD30-expressing mycosis fungoides, who have received prior systemic therapy.[L39789] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Intravenous; Parenteral |
50 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
50 mg/10.5mL
|
| Powder, for solution | Intravenous |
50 mg / vial
|
| Injection, solution, concentrate | Intravenous |
50 mg/1vial
|
| Injection, solution | Intravenous |
50 mg
|
| Powder | Intravenous |
50 mg
|
| Injection, powder, for solution | Intravenous drip |
50 mg
|
| Injection, powder, for solution | Intravenous |
50 mg
|
| Injection, powder, for solution | Intravenous |
5000000 mg
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P28908 | TNFRSF8 | Tumor necrosis factor receptor superfamily member 8 | Homo sapiens | binder|antibody|regulator | Link |
| enzyme | P08684 | CYP3A4 | Cytochrome P450 3A4 | Homo sapiens | substrate|inhibitor | Link |
| transporter | Q2M3G0 | ABCB5 | ATP-binding cassette sub-family B member 5 | Homo sapiens | substrate | Link |